AIQuartzabout 2 hours ago
Pfizer licenses AI startup for antibody design
.jpg&w=828&q=80&output=webp&we)
1 min read
Pfizer has licensed artificial intelligence technology from a biotechnology company to accelerate the development of therapeutic antibodies. This partnership aims to streamline complex molecular modeling processes and reduce time-to-market for new treatments.
Level
Hype check
Tap to vote and see what everyone thinks.
